Active, not recruitingPhase 3NCT02166463
Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma
Studying Classic Hodgkin lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Sharon M Castellino, MD, MScChildren's Oncology Group
- Intervention
- Bleomycin Sulfate(biological)
- Enrollment
- 600 enrolled
- Eligibility
- 2-22 years · All sexes
- Timeline
- 2015 – 2026
Study locations (30)
- Children's Hospital of Alabama, Birmingham, Alabama, United States
- USA Health Strada Patient Care Center, Mobile, Alabama, United States
- Providence Alaska Medical Center, Anchorage, Alaska, United States
- Banner Children's at Desert, Mesa, Arizona, United States
- Phoenix Childrens Hospital, Phoenix, Arizona, United States
- Banner University Medical Center - Tucson, Tucson, Arizona, United States
- Arkansas Children's Hospital, Little Rock, Arkansas, United States
- Kaiser Permanente Downey Medical Center, Downey, California, United States
- City of Hope Comprehensive Cancer Center, Duarte, California, United States
- Loma Linda University Medical Center, Loma Linda, California, United States
- Miller Children's and Women's Hospital Long Beach, Long Beach, California, United States
- Children's Hospital Los Angeles, Los Angeles, California, United States
- Cedars Sinai Medical Center, Los Angeles, California, United States
- Valley Children's Hospital, Madera, California, United States
- Kaiser Permanente-Oakland, Oakland, California, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02166463 on ClinicalTrials.govOther trials for Classic Hodgkin lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07275216Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard TreatmentCity of Hope Medical Center
- RECRUITINGPHASE2NCT07209059PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin LymphomaNational Research Center for Hematology, Russia
- RECRUITINGPHASE2NCT06984146Nivo40-AVD for Advanced Classic Hodgkin LymphomaNational Medical Research Radiological Centre of the Ministry of Health of Russia
- RECRUITINGPHASE2NCT06745076Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin LymphomaUniversity of Washington
- RECRUITINGPHASE1, PHASE2NCT06642792A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin LymphomaAkeso
- RECRUITINGPHASE2NCT06377540MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin LymphomaMasonic Cancer Center, University of Minnesota
- RECRUITINGPHASE2NCT07234487Comparison of AVD + Low-Dose Nivolumab vs. PET-Adapted BEACOPP-like in Advanced cHLSt. Petersburg State Pavlov Medical University
- RECRUITINGPHASE2NCT06812858PD-1 Inhibitors Maintenance for cHL Post-autoHCTSt. Petersburg State Pavlov Medical University